MIK665 (S64315)

Catalog No.S8836 Batch:S883601

Print

Technical Data

Formula

C47H44ClFN6O6S
Molecular Weight 875.41 CAS No. 1799631-75-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (114.23 mM)
Water Insoluble
 
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MIK665 (S64315) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1 with Ki value of 1.2 nM and has potential pro-apoptotic and antineoplastic activities.
Targets
Mcl-1 [1]
(Cell-free assay)
1.2 nM(Ki)
In vitro

S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1. [2]
In vivo

S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1. [2]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    H929 cells

  • Concentrations

    26 pM (Ki)

  • Incubation Time

    6 h

  • Method

    H929 cells were treated for 6 h with increasing concentration of S64315.
Animal Study:

[2]
  • Animal Models

    Female CB-17 SCID mice

  • Dosages

    12.5 mg/kg

  • Administration

    i.v.

Selleck's MIK665 (S64315) has been cited by 7 publications

Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy [ Nat Commun, 2024, 15(1):1581] PubMed: 38383524
Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction [ Cell Rep, 2023, 42(10):113176] PubMed: 37773750
Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma [ Biomedicines, 2023, 11(6)1666] PubMed: 37371761
Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy [ bioRxiv, 2023, 2023.02.14.528574] PubMed: 36824780
MCL1 Inhibitors S63845/MIK665 Plus Navitoclax Synergistically Kill Difficult-To-Treat Melanoma Cells [ Cell Death Dis, 2020, 8;11(6):443] PubMed: 32513939
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. [ Blood Adv, 2020, 4(5):819-829] PubMed: 32126142
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma [ Cancers (Basel), 2020, 12(8):E2182] PubMed: 32764384

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.